Gut microbiota mediated molecular events and therapy in liver diseases.

Gut microbiota is a community of microorganisms that reside in the gastrointestinal tract. An increasing number of studies has demonstrated that the gut-liver axis plays a critical role in liver homeostasis. Dysbiosis of gut microbiota can cause liver diseases, including nonalcoholic fatty liver disease and alcoholic liver disease. Preclinical and clinical investigations have substantiated that the metabolites and other molecules derived from gut microbiota and diet interaction function as mediators to cause liver fibrosis, cirrhosis, and final cancer. This effect has been demonstrated to be associated with dysregulation of intrahepatic immunity and liver metabolism. Targeting these findings have led to the development of novel preventive and therapeutic strategies. Here, we review the cellular and molecular mechanisms underlying gut microbiota-mediated impact on liver disease. We also summarize the advancement of gut microbiota-based therapeutic strategies in the control of liver diseases.

Data on the function of CDH17 in pancreatic cancer growth.

Data presented in this article are related to the research article entitled "Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death". To investigate the influence of CDH17 on human pancreatic cancer (PC), we performed gain and loss of CDH17 function with siRNA and recombinant plasmid to evaluate its impact on PC cell proliferation, colony formation, and migration. The data can be valuable for researchers interested in the study of oncogenic activity related to the CDH17 gene in PC growth and motility.